tiprankstipranks
Pacira Pharmaceuticals (DE:82P)
FRANKFURT:82P
Holding DE:82P?
Track your performance easily

Pacira Pharmaceuticals (82P) Income Statement

0 Followers

Pacira Pharmaceuticals Income Statement

Last quarter (Q3 2024), Pacira Pharmaceuticals's total revenue was $168.57M, an increase of 2.83% from the same quarter last year. In Q3, Pacira Pharmaceuticals's net income was $-143.47M. See Pacira Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 694.96M$ 674.98M$ 666.82M$ 541.53M$ 429.65M$ 421.03M
Cost of Revenue
$ 178.23M$ 184.67M$ 199.29M$ 140.25M$ 117.33M$ 106.71M
Gross Profit
$ 516.72M$ 490.31M$ 467.53M$ 401.28M$ 312.32M$ 314.31M
Operating Expense
$ 414.72M$ 402.99M$ 396.60M$ 268.44M$ 260.80M$ 278.60M
Operating Income
$ -64.91M$ 87.67M$ 60.02M$ 89.92M$ 46.35M$ 10.48M
Net Non Operating Interest Income Expense
$ 10.86M$ -8.86M$ -35.43M$ -30.85M$ -21.04M$ -16.25M
Other Income Expense
$ -41.59M$ -16.76M$ -22.19M$ 2.67M$ 122.55M$ 4.98M
Pretax Income
$ -54.91M$ 61.70M$ 13.30M$ 56.40M$ 20.09M$ -10.75M
Tax Provision
$ 35.82M$ 19.75M$ -2.61M$ 14.42M$ -125.43M$ 268.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -90.73M$ 41.95M$ 15.91M$ 41.98M$ 145.52M$ 39.44M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 255.29M$ 587.65M$ 595.90M$ 408.70M$ 378.13M$ 385.32M
Net Income From Continuing And Discontinued Operation
$ -90.73M$ 41.95M$ 15.91M$ 41.98M$ 145.52M$ -11.02M
Normalized Income
$ 79.93M-----
Interest Expense
------
EBIT
$ -74.84M$ 79.01M$ 48.88M$ 85.40M$ 43.60M$ 21.07M
EBITDA
$ -14.94M$ 154.59M$ 140.38M$ 113.95M$ 63.51M$ 56.10M
Currency in USD

Pacira Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis